PCOS Is Now PMOS — And Why That One Letter Will Change How You're Treated

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN • U.S. Navy veteran (13 years) • Author, The Book of Hormones • Founder, Gaya Wellness

Published May 22, 2026 • 11-minute read

Let me tell you what just happened, and why you should care even if you've never been diagnosed with PCOS.

Two weeks ago, in a paper published in The Lancet, an international consensus panel officially threw out the name "polycystic ovary syndrome." After 14 years of work, surveys of approximately 22,000 patients and clinicians, and collaboration across 56 organizations, the condition has a new name: polyendocrine metabolic ovarian syndrome — PMOS.

One letter changed. The framing of an entire disease changed with it.

Here's what the medical establishment is now saying out loud, in a peer-reviewed journal, with the signatures of the Endocrine Society and 50-plus other organizations attached: the old name was inaccurate. It implied a cyst disorder that doesn't actually exist. It obscured the metabolic and endocrine features that drive the real long-term damage. And it contributed to delayed diagnosis, fragmented care, and stigma for the 170 million women living with this condition.

That is not a small admission. That is a 90-year apology dressed up as a press release.

I'm going to walk you through what actually changed, why it matters specifically for women in midlife, and what real PMOS care looks like — because the rename only matters if the care changes with it.

What Just Happened: The May 2026 Lancet Rename

On May 12, 2026, The Lancet published the consensus paper from Professor Helena Teede and colleagues formally renaming PCOS to polyendocrine metabolic ovarian syndrome. The new acronym is PMOS. The change was presented simultaneously at the European Congress of Endocrinology in Prague.

The process took 14 years. It involved more than 50 patient and professional organizations, including the Endocrine Society, ACOG-equivalent bodies around the world, and patient advocacy groups across six continents. Approximately 22,000 people contributed to the surveys and workshops that informed the final name. The most recent survey alone, conducted in 2025, captured responses from nearly 15,000 stakeholders.

The authors of the Lancet paper were direct about why the old name had to go. They called it "inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features, and contributing to delayed diagnosis, fragmented care, and stigma." That is unusually sharp language for a consensus document. It is the medical establishment acknowledging that the framing itself was causing harm.

The rollout will take three years. Clinical guidelines used in 195 countries will be updated. Disease classification systems will follow. If you were previously diagnosed with PCOS, you now have PMOS. The diagnostic criteria themselves haven't changed — the Rotterdam criteria still require two of three features: hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology on ultrasound. What changes is the clinical framing of what the diagnosis actually means.

Why the Old Name Did Real Damage

Here's the origin story nobody talks about. About a century ago, surgeons operating on a woman with irregular cycles, high androgens, and infertility noticed what looked like small sacs on her ovaries. They assumed these were cysts. They named her condition "polycystic ovary syndrome" based on what they could see with the surgical tools of the 1930s.

It turned out they were wrong. As the Lancet authors and accompanying coverage have now confirmed, those "cysts" are not actually pathological cysts at all. They are immature follicles that failed to develop into a dominant ovulating follicle — a downstream symptom of a much deeper hormonal disturbance, not the disease itself.

But the name stuck. And for 90 years, it shaped how the condition was diagnosed, who diagnosed it, and what got treated.

Three specific harms came from that framing:

1. The condition was routed to gynecologists when many women needed endocrinologists, cardiologists, and metabolic specialists. Because the name pointed to the ovaries, the diagnostic pipeline ran through reproductive medicine. The insulin resistance, the cardiovascular risk, the liver dysfunction, the lipid abnormalities — those were treated as side notes, if they were treated at all. As Dr. Andrea Dunaif of Mount Sinai has pointed out, it wasn't until the 1980s that the insulin resistance connection was even formally established in the literature. Forty years on, most women with this condition still aren't being screened for it properly.

2. The condition was framed as a fertility problem. Most women with PMOS were diagnosed only when they tried to get pregnant and couldn't. By that point, the metabolic horse had already left the barn. They had been insulin-resistant for a decade. They had been gaining visceral fat for a decade. Their cardiovascular risk had been quietly compounding for a decade. The window for early intervention was gone — missed because the name told everyone to look at the ovaries.

3. An estimated 70% of cases worldwide remain undiagnosed. That figure comes from the World Health Organization and has been confirmed in the current Lancet consensus. Out of 170 million women globally, more than 100 million are living with an unrecognized endocrine and metabolic disorder. Some of them have been told their cycles are "just irregular." Some have been told to lose weight. Some have been put on antidepressants for the mood symptoms. Almost none have been told they have a lifelong metabolic syndrome that requires active management.

That is not a vocabulary problem. That is a structural failure of how medicine handles women's health.

What "Polyendocrine Metabolic" Actually Means for Your Body

Let me unpack the new name, because every word in it was chosen for a reason.

Polyendocrine — meaning multiple endocrine systems are simultaneously disrupted. PMOS is not one hormone gone wrong. It is a coordinated dysfunction involving insulin signaling, androgens (testosterone and DHEA-S), luteinizing hormone (LH), follicle-stimulating hormone (FSH), and neuroendocrine pathways in the hypothalamus. The 2024 mouse studies on GnRH pulse generator activity have shown that the LH pulsatility in PMOS is up to threefold higher than in unaffected women, both in lean and obese phenotypes. This is a brain-level dysregulation, not just an ovary problem.

Metabolic — and this is the part that has been hiding in plain sight for 90 years. According to the Lancet consensus, insulin resistance is common in women with PMOS, including in those at a healthy weight. Up to 30% of women with PMOS have a lean phenotype: normal BMI, normal-looking labs on a basic primary care panel, and significant underlying insulin resistance that nobody is screening for.

The downstream metabolic consequences are well-documented and now formally acknowledged in the rename. Women with PMOS have elevated risk of:

• Type 2 diabetes — including gestational diabetes during pregnancy
• Cardiovascular disease — confirmed in a 2024 meta-analysis in the Journal of the American Heart Association showing elevated clinical cardiovascular disease in this population
• Dyslipidemia — abnormal cholesterol and triglyceride patterns
• Non-alcoholic fatty liver disease (NAFLD) — now reframed as metabolic dysfunction-associated steatotic liver disease (MASLD)
• Hypertension
• Obstructive sleep apnea
• Depression and anxiety — not as side effects, but as part of the endocrine disorder itself

Ovarian — retained in the name because ovarian dysfunction is still part of the picture. Ovulatory disturbances, androgen production from the ovaries, and the morphology changes visible on ultrasound are real features. But they are now one component of a multi-system disorder, not the whole story.

The Lancet authors made one more important point: the therapeutic framing now shifts toward targeting the upstream drivers — insulin resistance and neuroendocrine dysfunction — alongside the reproductive symptoms. You treat the metabolism first. The ovulation often follows.

The Diagnostic Delay That Costs Women Their Cardiovascular Health

Here is what I want you to understand about why this rename matters specifically for midlife women.

Most women with PMOS who get diagnosed at all are diagnosed in their late 20s or early 30s during a fertility workup. By that point, they have typically had irregular cycles since adolescence, weight changes since their late teens, and undiagnosed insulin resistance for somewhere between 10 and 20 years.

What that means clinically: by the time most women with PMOS hit perimenopause, they have already been metabolically dysregulated for two decades. Their visceral fat is established. Their lipid panel is trending wrong. Their fasting insulin has been elevated long enough to start damaging the vascular endothelium. And nobody has told them.

Then perimenopause hits. Estrogen starts to decline. And estrogen, it turns out, is one of the most powerful metabolic regulators in the female body — it preserves insulin sensitivity, supports lean muscle mass, and protects against visceral fat accumulation. When it drops, the underlying PMOS metabolism gets worse. Much worse.

This is the cohort I see in my practice every week. A 44-year-old woman comes in. She has a history of "PCOS" that her gynecologist told her about in her 20s, treated with birth control, and never mentioned again. She is now in perimenopause. She has gained 25 pounds in two years that won't come off no matter what she does. Her lipids are creeping up. Her fasting glucose is in the high-normal range. Her A1c is 5.8. Her primary care doctor told her everything is "normal."

It is not normal. It is undermanaged PMOS colliding with declining estrogen. And it requires a completely different approach than what she has been receiving for 20 years.

What Real PMOS Care Looks Like

The rename only matters if the care changes with it. Here is what an evidence-based PMOS workup actually looks like — and what we do at Gaya Wellness for women in this position.

A complete metabolic and endocrine panel — not "normal labs." Total and free testosterone. DHEA-S. SHBG. Fasting insulin and fasting glucose, with HOMA-IR calculated. HbA1c. A 2-hour oral glucose tolerance test if there is any clinical suspicion of insulin resistance. Full lipid panel including ApoB. AMH, LH, and FSH. Full thyroid panel including antibodies. Vitamin D. Liver enzymes given the NAFLD/MASLD connection. Inflammatory markers including hsCRP. This is a 50+ biomarker workup. It is the standard of care for a multi-system endocrine disorder. It is not what most women get in a 15-minute primary care visit.

Cardiovascular risk assessment as a baseline, not an afterthought. Given the 2024 meta-analytic evidence of elevated cardiovascular disease in this population, a woman with PMOS deserves a real cardiometabolic risk evaluation — not a calculator that assumes she is a generic 45-year-old without a 20-year history of insulin resistance.

Treatment that targets the upstream driver, not just the symptoms. For most women with PMOS, that means addressing insulin resistance directly — through nutrition, resistance training, metformin or inositol where appropriate, and in midlife, often hormone replacement therapy to restore the metabolic protection that estrogen provides. For women whose insulin resistance is significant and not responding to first-line approaches, GLP-1 medications like semaglutide and tirzepatide are now part of the toolkit.

This is what our Hormonal Agency™ program is built for. A board-certified OB/GYN who actually understands the endocrine system. A 50+ biomarker panel that catches what standard labs miss. A treatment plan that addresses the underlying hormonal disruption instead of treating each symptom in a silo. And ongoing physician oversight rather than a one-and-done prescription.

• Agency Rx — $149/mo: Comprehensive hormonal evaluation and prescription management through a board-certified OB/GYN.
• Complete — $249/mo: Everything in Agency Rx plus 50+ biomarker labs, full metabolic and endocrine workup, and ongoing optimization.
• Total — $349/mo: The complete protocol — hormonal optimization, metabolic management, and the personalized clinical oversight a multi-system endocrine disorder actually requires.

This Isn't Just a Twenty-Something Problem

There is a stubborn cultural assumption that PCOS — now PMOS — is a young woman's fertility problem. You get diagnosed in your 20s. You take birth control. You try to get pregnant. You get treated. You move on.

That framing is wrong, and it has cost a generation of women their cardiovascular and metabolic health.

PMOS is a lifelong condition. The reproductive features resolve when periods stop, but the underlying metabolic dysfunction does not. It intensifies. Women who entered menopause with a PMOS history have higher rates of type 2 diabetes, cardiovascular disease, and metabolic syndrome in their 50s and 60s than women without that history. The condition follows them.

That is precisely why the rename matters for the women I treat at Gaya. A 47-year-old woman with a PMOS history is not done with the condition. She is in the highest-risk phase of it. Her declining estrogen is removing one of the few metabolic buffers her body had. And the standard primary care framework — check the A1c, recommend more exercise, prescribe a statin if things get bad enough — is not equipped to address what is actually happening.

What she needs is the full picture. A clinician who understands both the lifelong endocrine disorder and the menopausal transition. A treatment plan that integrates metabolic management, hormone optimization, and cardiovascular risk reduction. And a long view — because PMOS is not something you treat for a year. It is something you manage for the rest of your life.

The Name Changed. Now Demand the Care Changes Too.

Here's the truth nobody is going to put in a press release: a name change in The Lancet does not automatically translate to better care at your local doctor's office. The rollout is planned over three years. Clinical guidelines in 195 countries will be updated. Medical schools will eventually catch up. Insurance billing codes will eventually shift.

None of that helps you tomorrow.

What helps you tomorrow is knowing that this rename gives you, the patient, language and legitimacy. You are not "just" being treated for irregular cycles. You have a multi-system endocrine and metabolic disorder. You deserve a workup that reflects that. You deserve cardiovascular risk assessment. You deserve insulin resistance screening. You deserve to be told what is actually going on in your body — and what you can do about it.

If you have ever been dismissed, told to lose weight, or handed a prescription for the pill and shown the door — the medical establishment just officially conceded that the framing you were treated under was wrong. That is your opening to ask for more. To demand more. To find a clinician who is practicing in 2026, not 1990.

You haven't been failing your body. The system has been failing you. The name finally changed. Now the care needs to catch up.

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN, U.S. Navy veteran, and founder of Gaya Wellness. Dr. Patel leads physician-managed programs in medical weight loss, hormone optimization, and longevity medicine for women in midlife and beyond.